IBC Meeting Minutes Cleveland Clinic Main Campus

Date:		Location:	
August 27 th , 2025		Zoom	
IBC Member Attendance:			
☐ Ahern, Philip	⊠ DiDonato, Jo	oseph	□ Dragan, Amanda (BSO)
☐ Fox, Alan	⊠ Hajjar, Adel	ine	
☐ Kerr, Travis	□ Lindner, Dan	niel	⊠ McDonald, Christine (IBC Chair)
	⊠ Southern, Bı	rian	Speranza, Emily
⊠ Such, Kimberly			
Guests: Anthony Santilli*, Anno Abby Bifano*, Dylan Champer* * Cleveland Clinic Main Camp	** US		
** Cleveland Clinic Florida Re	search & Innova	,	RIC)
Call To Order:		Adjourn:	
2:32 PM		4:22 PM	

I. Review of July 30th, 2025 Meeting Minutes

Committee Comments:									
N/A									
Motion Approval:	For:	Against:	Abstain:						
		1-5	11000001111						

II. Administrative Business

- **a.** Committee presented with Expedited Review items and personnel additions.
- **b.** Incident Report: No incidents were reported since the previous meeting.
- **c.** Lab Audits: Members were presented with and informed of Annual Lab Audits and Preliminary Audits occurring during the month of August 2025. No major deficiencies identified.

III. Clinical Research:

a. Applications:

Clinical Application #1	Protocol ID: Application #1	PI: Rachitskaya	Biosafety Level: BSL1	NIH Cat.: III-C-1, III-E
Project Title:			DSE1	<u> </u>

•	· ·		*	1		, Phase 3 Study
to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants						
with Neovascular Age-Related Macular Degeneration (ARTEMIS) Associated Grant Numbers:						
Non-NIH Funding	umbers:					
Protocol Summary:						
_	n of recombinant	replica	ation-incom	netent, ader	o-associa	ted virus (AAV)
viral vector to		,, repire		ipotoni, adoi	io dissour	wed (In It)
Function/Nature of R	ecombinant Gene	es to be	Expressed:			
□ N/A □ Oncogene						
☐ Immunomodulatory	□ Toxin □ An	tibiotic 1	Resistance	☐ Reporters	☐ Cell N	Metabolism
☐ Other						
Species of Pasambin	ant Ganas ta ba E	Evpross	d.			
Species of Recombin □ N/A □ Human □	ant Genes to be 1 ☐ Murine ☐ Bacte	-		ther		
	I Warme in Back	711a1 L	viiai 🗆 O	ilici		
Risk Assessment Dis	scussion:		Facilitie	s, Procedur	es, and S	afety Practices
⊠ Yes □ No			Reviewe	ed:		
			⊠ Yes	□ No		
PI/Supervisor Train	ing:		Handler	Training:		
⊠ Yes □ No			⊠ Yes	□ No		
Discussion/Required Modifications:						
N/A						
N/A						
				T		
N/A Motion Approval: Approved		For:	Against:	Abstain:	Recuses	_
Motion Approval:		For: 9	Against:	Abstain:	Recuse:	Not Present:
Motion Approval:			_			_
Motion Approval: Approved	Protocol ID:	9	0	0	0	1
Motion Approval: Approved Clinical	Protocol ID: Application #2	9	_		ty 0	_
Motion Approval: Approved	Protocol ID: Application #2	9	0 PI:	Biosafet	ty 0	NIH Cat.:
Motion Approval: Approved Clinical Application #2 Project Title:	Application #2	9 Bri	PI: unstein	Biosafet Level: BSL2	ty	NIH Cat.: III-C-1, III-E
Motion Approval: Approved Clinical Application #2 Project Title: A Phase I, Multicente	Application #2	9 Broudy to I	PI: unstein Evaluate the	Biosafet Level: BSL2	ty erability, 0	NIH Cat.: III-C-1, III-E
Motion Approval: Approved Clinical Application #2 Project Title: A Phase I, Multicente Kinetics, and Pharma	Application #2 er, Open Label St codynamics of P	9 Broudy to I	PI: unstein Evaluate the	Biosafet Level: BSL2	ty erability, 0	NIH Cat.: III-C-1, III-E
Clinical Application #2 Project Title: A Phase I, Multicente Kinetics, and Pharma Associated Grant No.	Application #2 er, Open Label St codynamics of P	9 Broudy to I	PI: unstein Evaluate the	Biosafet Level: BSL2	ty erability, 0	NIH Cat.: III-C-1, III-E
Clinical Application #2 Project Title: A Phase I, Multicente Kinetics, and Pharma Associated Grant Non-NIH Funding	Application #2 er, Open Label St codynamics of P	9 Broudy to I	PI: unstein Evaluate the	Biosafet Level: BSL2	ty erability, 0	NIH Cat.: III-C-1, III-E
Clinical Application #2 Project Title: A Phase I, Multicente Kinetics, and Pharma Associated Grant Non-NIH Funding Protocol Summary:	Application #2 er, Open Label St codynamics of P	9 Broudy to I	PI: unstein Evaluate the	Biosafet Level: BSL2 Safety, Tole O1 in Patien	erability, of	NIH Cat.: III-C-1, III-E Cellular ultiple Sclerosis
Clinical Application #2 Project Title: A Phase I, Multicente Kinetics, and Pharma Associated Grant Non-NIH Funding Protocol Summary: Administration	Application #2 er, Open Label St codynamics of P umbers: on of Transposon	Bruudy to I -CD19C	PI: unstein Evaluate the CD20-ALLO	Biosafet Level: BSL2 Safety, Tole O1 in Patien	erability, of	NIH Cat.: III-C-1, III-E Cellular ultiple Sclerosis
Clinical Application #2 Project Title: A Phase I, Multicente Kinetics, and Pharma Associated Grant Non-NIH Funding Protocol Summary: Administration	Application #2 er, Open Label St codynamics of P umbers: on of Transposon ecombinant Gene	Bruudy to I-CD19C	PI: unstein Evaluate the CD20-ALLO ed and Cas- Expressed:	Biosafet Level: BSL2 e Safety, Tole O1 in Patien	erability, of ts with M	NIH Cat.: III-C-1, III-E Cellular ultiple Sclerosis
Clinical Application #2 Project Title: A Phase I, Multicente Kinetics, and Pharma Associated Grant Non-NIH Funding Protocol Summary: Administration	Application #2 er, Open Label St codynamics of P umbers: on of Transposon ecombinant Gene Tumor Suppre	Bruudy to H-CD19C	O PI: unstein Evaluate the CD20-ALLO ed and Cas- Expressed: ne Struct	Biosafer Level: BSL2 Safety, Tolo O1 in Patien CLOVER eattural	erability, of the with M	NIH Cat.: III-C-1, III-E Cellular ultiple Sclerosis s to humans

Species of Recombin	ant Genes to be I	Expresso	-d·			
□ N/A □ Human □ Murine □ Bacterial □ Viral □ Other						
	i manne ii baet	оттат <u></u>	viiui 🗀 Ot			
Risk Assessment Dis	scussion:		Facilitie	s. Procedur	es, and Sa	fety Practices
⊠ Yes □ No	, C C			ed (Y/N):	00, 0010	100, 11000000
			⊠ Yes	□ No		
PI/Supervisor Train	ing (Y/N):		Handler	Training (Y/N):	
⊠ Yes □ No			⊠ Yes			
Discussion/Required	l Modifications:					
_	e edits and updat					
7 Kammisuativ	e carts and apact	.03				
Motion Approval:					_	
Approved w/ Admin	istrative	For:	Against:	Abstain:	Recuse:	Not Present:
Revisions		10	0	0	0	0
		I.		I		
		T				
Clinical	Protocol ID:		PI:	Biosafet	•	NIH Cat.:
Application #3	Application #3	(Caimi	Level:		III-C-1
				BSL2		
Project Title:	. 10 D 1	. 1 . 1	1 ,	C , ,1	TECEL D	A @
Expanded Access Pro						
(afamitresgene autole	eucel, suspension	for intr	avenous inf	usion) Com	mercial Re	lease
Specification						
Associated Grant No.	umpers:					
Non-NIH Funding Protocol Summary:						
_	on of raplication	dafaativ	o lontivirol	transduced i	aalla ta hur	nong
Administration	on of replication	uerectiv	e lentivirai	transduced (sens to nui	IIalis
Function/Nature of R	ecombinant Gen	es to be	Expressed:			
□ N/A □ Oncogene			-	tural 🗆 Sig	nalina 🗆	Antimicrobial
☐ IVA ☐ Oncogene				_	_	
☐ Other		indione	Resistance	□ Reporters	□ CCII WI	Ctabolisiii
Species of Recombin	ant Genes to be I	Expresse	ed.			
\square N/A \square Human \square		-	·	ther		
I TWIT I Trainer L	i widilile 🗀 Baci	iciiai L	7 T T T T T T T T T T T T T T T T T T T	tiloi		
Risk Assessment Dis	scussion:		Facilitie	s. Procedur	es, and Sa	fety Practices
⊠ Yes □ No	, C C		Reviewe	·	00, 0010	1005 1 10001000
			⊠ Yes	□ No		
PI/Supervisor Train	ing:			Training:		
⊠ Yes □ No	-		⊠ Yes	□ No		
Discussion/Required	l Modifications:					
N/A						
Motion Approval:		For:	Against:	Abstain:	Recuse:	Not Present:

Approved	10	0	0	0	0

IV. Non-Clinical Research:

a. New Applications:

Basic Research	Protocol ID:		PI:	Biosafet	ty	NIH Cat.:					
Application #1	Application #1	Dł	nawan	Level:	III-	D-1-a, III-D-3-					
				BSL2		a					
Project Title:											
miRNA and mRNA affecting glioma survival											
Associated Grant Numbers: Non-NIH Funding											
Protocol Summary:											
 Generation of 	replication defec	tive len	tiviral parti	cles, transdu	ction of tis	ssue culture					
cells.	-		-								
• Human-derive	ed material										
Function/Nature of R	ecombinant Gene	es to be	Expressed:								
□ N/A □ Oncogene	☐ Tumor Suppre	ssor Gen	e 🗆 Struc	tural 🗆 Sig	naling 🗆 🛭	Antimicrobial					
	□ Toxin ⊠ Aı	ntibiotic	Resistance	⊠ Reporters	s \boxtimes Cell	Metabolism					
⊠ Other											
Species of Recombin		-									
□ N/A ⊠ Human [☐ Murine ☐ Bact	erial L	∣Viral ⊠ (Other							
Risk Assessment Dis	scussion:		Facilitie	s. Procedur	es. and Sa	fety Practices					
⊠ Yes □ No			Reviewe	*	es, and sa	ioty i i decices					
_ 100 _ 100			⊠ Yes	□ No							
PI/Supervisor Train	ing:		Handler	Training:							
⊠ Yes □ No	8.		⊠ Yes	□ No							
Discussion/Required	l Modifications:										
 Include a state 	ement that Core f	acilities	will be info	ormed of BS	L and orig	in of unfixed					
samples.					Č						
•											
Motion Approval:		For:	Against:	Abstain:	Recuse:	Not Present:					
Approved w/ Admin	istrative	10	Against:	Abstain:	()	Not Present:					
Revisions		10	U	U	U	U					

Basic Research	Protocol ID:	PI:	Biosafety	NIH Cat.:						
Application #2	Application #2	Valujskikh	Level:	III-D-4-a						
			BSL1, ABSL1							
Project Title:										
Investigations into tu	Investigations into tumor development in transplant recipients									

Associated Grant No Non-NIH Funding	umbers:					
Protocol Summary:						
Administration	on of transduced of	cells <i>in</i> v	vivo.			
Function/Nature of R	ecombinant Gene	es to be	Expressed:			
□ N/A □ Oncogene			_	tural □ Sio	naling \square	Antimicrobial
☐ Immunomodulatory				_	_	
	L TOAIII L TII		Constance	△ Reporters		victaoonsin
☐ Other						
Consider of December		·	1.			
Species of Recombination		-		1		
□ N/A □ Human □	」Murine □ Bact	erial 🗀	Viral 🗵 C	ther		
Risk Assessment Dis	cussion:		Facilitie	s, Procedur	es, and Sa	fety Practices
⊠ Yes □ No			Reviewe	d:		
			⊠ Yes	□ No		
PI/Supervisor Train	ing:			Training:		
⊠ Yes □ No	s .		⊠ Yes	□ No		
Discussion/Required	Madifications		<u> </u>	<u> </u>		
-			1			
-	location for <i>in viv</i>	-				
 Update "Poter 	ntial Route of Exp	osure"	to reflect th	nese cells are	e not consi	dered a
respiratory ha	zard.					
Motion Approval:		E.	A	Abstain:	Danuari	Not Duogomts
Approved w/ Admin	istrative	For:	Against:		Recuse:	Not Present:
Revisions		10	0	0	0	0
				_	1	
Basic Research	Protocol ID:		PI:	Biosafet	v	NIH Cat.:
Application #3	Application #3		Γiek	Level:	•	D-1-a, III-D-3-
Application #5	rippiication #5	1	IIOK	BSL2, AB		III-D-4-b, III-E
Project Title:				DSL2, AD	3L2 a, 1	III-D- 1 -0, III-L
	in alioma					
Targeting ferroptosis						
Associated Grant No	umbers:					
4R00CA279896						
Protocol Summary:					0	1.
	replication defec		-		iction of ti	ssue culture
cells and administration of transduced cells <i>in vivo</i>						
transfection of tissue culture cells						
Human-derived materials						
Everation/Network of D			C			
Function/Nature of R			-			
	☐ Tumor Suppre			_	_	
☐ Immunomodulatory	□ Toxin ⊠ An	tibiotic I	Resistance	⊠ Reporters	s ⊠ Cell	Metabolism
⊠ Other						

Species of Recombination		_				
│□ N/A □ Human □	☐ Murine ☐ Bact	terial \square	Viral ⊠ C	Other		
Risk Assessment Dis	cussion:			*	es, and Sa	fety Practices
⊠ Yes □ No			Reviewe			
DI/Com ourrison Tuoin	·		⊠ Yes	□ No		
PI/Supervisor Train ⊠ Yes □ No	ing:		Handler ⊠ Yes	Training: □ No		
Discussion/Required	Modifications		△ res	□ NO		
_	te if genes being	transduc	red are once	ogenes or tu	ımor siinnr	essor genes
	ould be spelled or				illioi suppi	essor genes.
=	g numbers for cel		-		the listed	aall lina
-			-			
• Clarity in text is choosing to	what PPE is requ	uirea ior	in vivo pro	ocedures vs	wnai addii	ionai PPE lao
	wear. ect that used disp	oga hl a g	, min and , , , , i	ll ha digaard	ad dinaatly	into o choma
 Update to reflection 	ect mat used disp	osable s	yringes wii	ii de discard	ed directly	into a snarps
Administrativ	o undatos					
Aummsuauv	e updates					
Motion Approval:						
Approved w/ Admin	istrative	For:	Against:	Abstain:	Recuse:	Not Present:
Revisions		10	0	0	0	0
		N		ı	l .	1
Basic Research	Protocol ID:	1	DY.	D: C-	<u></u>	NIII C-4
			PI:	Biosafet Level:	•	NIH Cat.: III-D-4-b
Application #4	Application #4	Stapp	penbeck	BSL2, AB		111-D-4-0
Project Title:				DSL2, AD	SLZ	
Ovarian, Breast, Lung	Colon and Pro	state Ca	ncer Vaccii	nation with	Retired Pro	otein Antigens
and Combination Imr	•	Biaic Ca	ncer vacen	nation with	recined 110	stem i magens
Associated Grant Nu						
Non-NIH Funding						
Protocol Summary:						
	n of lentiviral trai	nsduced	cells in viv	0		
Function/Nature of R	ecombinant Gene	es to be l	Expressed:			
□ N/A □ Oncogene				tural 🗆 Sig	naling \square	Antimicrobial
☐ Immunomodulatory				_	_	
☐ Other				1		
Species of Recombination	ant Genes to be E	Expresse	<u>d:</u>			
□ N/A □ Human □		_		ther		
Risk Assessment Dis	cussion:				es, and Sa	fety Practices
⊠ Yes □ No			Reviewe	d:		

			⊠ Yes	□ No				
PI/Supervisor Train	PI/Supervisor Training: Handler Training:							
⊠ Yes □ No			⊠ Yes	□ No				
Discussion/Required								
Indicate IBC	protocol will be A	ABSL2.						
Motion Approval:								
Approved w/ Administrative For: Against: Abstain: Recuse: Not Fi								
Revisions 10 0 0 0								
		L						
1 NY A 19		• • • •	NIII C :					
b. New Appli	ications not appl	icable t	o NIH Guid	lelines:				
Basic Research	Protocol ID:		PI:	Biosafet	ty	NIH Cat.:		
Application #5	Application #5	Hai	rrington	Level:		N/A		
				BSL2+	-			
Project Title:	. 10, 1D		136.1	1 13371	1 0	· ·		
Evaluation of Optimi								
for Multicenter Surve Associated Grant N		care Fa	cinty-Assoc	iated nontur	berculous N	лусовастега		
Non-NIH Funding	umpers:							
Protocol Summary:								
_	osis (NTM) isolat	tes and	shipment of	cultures to	collaborato	rs at Duke		
University	,		1					
Subculture of	Mycobacterium s	ssp.						
Function/Nature of R								
	* *			_	_			
☐ Immunomodulatory	☐ Toxin ☐ An	tibiotic	Resistance	☐ Reporters	☐ Cell M	letabolism		
☐ Other								
Species of Recombin	ant Conos to be E	Vprogg	d.					
\boxtimes N/A \square Human		-		ther				
	in what the in Buch		o vii ai o	unoi				
Risk Assessment Di	scussion:		Facilities	s, Procedur	es, and Sa	fety Practices		
⊠ Yes □ No			Reviewe	*	,	·		
			⊠ Yes	□ No				
PI/Supervisor Train	ning:		Handler	Training:				
⊠ Yes □ No			⊠ Yes	□ No				
Discussion/Required	d Modifications:							
• N/A								
Motion Annewale		For:	Against:	Abstain:	Recuse:	Not Present:		
Motion Approval: Approved		10	Agamst:	Abstain:	0	0		
11pproveu		10	L		U	U		

c. Renewals:

Basic Research	Protocol ID:		PI:	Biosafet	ty	NIH Cat.:				
Renewal #1	IBC 1809	P	iuzzi	Level:		III-D-1-a, III-D-				
				BSL2, AB	SL2	4-b				
Project Titles:										
Efficacy of thermogel solution in <i>in vivo</i> model of knee periprosthetic joint infection (PJI)										
Associated Grant Numbers:										
Non-NIH Funding										
Protocol Summary:										
Administration	on of wild-type an	d recon	nbinant <i>Sta_l</i>	phylococcus	spp. in	vivo				
Function/Nature of R	ecombinant Gene	s to be	Expressed:							
□ N/A □ Oncogene				tural □ Sig	naling	☐ Antimicrobial				
☐ Immunomodulatory	• •			⊠ Reporters	_	ll Metabolism				
□ Other	_ 19 11			_ 110p 011010		11 1710000 0 110111				
_ = =										
Species of Recombin	ant Genes to be E	xpresse	<u>d:</u>							
□ N/A □ Human □	☐ Murine ☐ Bacte	rial 🗆	Viral ⊠ O	ther						
Risk Assessment Dis	scussion:		Facilitie	s, Procedur	es, and	Safety Practices				
⊠ Yes □ No			Reviewe	ed:						
			⊠ Yes	□ No						
PI/Supervisor Train	ing:		Handler	Training:						
⊠ Yes □ No			⊠ Yes	□ No						
Discussion/Required	l Modifications:									
 Indicate shoe 	covers will be ren	noved p	rior to exit	ing the facili	ity.					
• If possible, sy	ringes should be	prepare	d outside of	f the facility	to avoid	unnecessary				
sharps manipu	ulations during in	vivo pro	ocedures.							
 Update method 	ds of disposal for	biohaz	ardous was	te from in vi	vo proce	edures.				
_	_				_					
Motion Approval:		For:	A gainst:	Abstain:	Recuse	e: Not Present:				
Approved w/ Admin	istrative	10	Against:	Abstain: 0	()	o Not Present:				
Revisions		10	U	U	U	U				

Basic Research	Protocol ID:	PI:	Biosafety	NIH Cat.:
Renewal #2	IBC2124	Chen	Level:	III-D-1-a, III-D-
			BSL2, ABSL2	3-a, III-D-4-b
Project Titles:				
Melanoma Signaling	Pathways			
Associated Grant N	umbers:			
Non-NIH Funding				

Protocol Summary:						
	replication defec	ctive len	itivirus parti	cles, transdi	uction of	tissue culture
cells and adm	inistration in vivo) .	•			
Human-derive	ed material.					
Function/Nature of R □ N/A □ Oncogene				tural ⊠ Sig	maling	☐ Antimicrobial
☐ Immunomodulatory ☐ Other				-	_	
⊠ Other						
Species of Recombin	ant Genes to be I	Expresse	ed:			
=	⊠ Murine □ Bact	-		ther		
Risk Assessment Dis	scussion:		Facilitie	s, Procedur	es, and S	Safety Practices
⊠ Yes □ No			Reviewe	d:		
			⊠ Yes	□ No		
PI/Supervisor Train	ing:		Handler	Training:		
⊠ Yes □ No			⊠ Yes	□ No		
Discussion/Required						
	nes are oncogene	s or tun	nor suppress	ors and upd	ate relev	ant sections of
application						
	ne is being partial	lly expr	essed and us	sed as a tag,	or if the	full gene is
being express				-		
	ement that Core f	facility v	will be made	e aware of B	SSL of sa	mples being
assessed.						
Motion Approval:						
Approved w/ Admin	iistrative	For:	Against:	Abstain:	Recuse	: Not Present:
Revisions	isti ative	10	0	0	0	0
110 (1510115						
d. Renewa	als Not Applicab	ole to N	IH Guidelii	nes:		
Basic Research	Protocol ID:		PI:	Biosafe	tv	NIH Cat.:
Renewal #3	IBC 1718	F	Rieder	Level:	•	N/A
				BSL1, BS		
Project Titles:		•	•	·	•	
The role of fungi in the	ne pathogenesis o	of intest	inal fibrosis			
Associated Grant N	umbers:					
Non-NIH Funding						
Protocol Summary:						
 Acquisition or 	f Candida spp. fc	or cultur	ing and co-	culture with	tissue cu	ılture cells
. II	- community					
• Human-derive	ed materials					
	ed materials					
Function/Nature of R ⊠ N/A □ Oncogene	ed materials					

□ Immunomodulatory □ Toxin □ Antibiotic Resistance □ Reporters □ Cell Metabolism

□ Other							
Species of Recombin	ant Genes to be I	Express	ed:				
⊠ N/A □ Human		-		ther			
Risk Assessment Dis	scussion:			*	es, and	Sa	fety Practices
⊠ Yes □ No			Reviewe				
PI/Supervisor Train	ing:			☐ No Training:			
⊠ Yes □ No	8.		⊠ Yes	□ No			
Discussion/Required	d Modifications:						
	for Candida spp.						
	ite an alternative					fect	tants available
with a contact	t time of 1 min ar	e availa	ible for thes	e organisms	•		
Motion Approval:		For:	Against:	Abstain:	Recus	e:	Not Present:
Approved w/ Admir Revision	nistrative	9	0	0	0		1
Kevision							
					. 1		
Basic Research	Protocol ID:		PI:	Biosafe	•	NIH Cat.: N/A	
Renewal #4	IBC2125		Scott	Level: BSL2		IN/A	
Project Titles: The effect of genetic sensitivity	background on th	ne evolu	ıtion of anti	biotic resista	ance and	l co	llateral
Associated Grant N R37 CA244613-01	umbers:						
Protocol Summary:							
_	nd propagation of	f bacter	ia in the pre	sence of ant	ibiotics.		
 Identification 	of antibiotic-resi	stant is	olates.				
Analysis of back	iofilm formation	and ant	ibiotic resis	tance			
Function/Nature of R ⊠ N/A □ Oncogene			-	etural □ Sig	onaling	П	Antimicrobial
☐ Immunomodulatory				-	_		
☐ Other				1			
		_					
Species of Recombin				.1			
⊠ N/A □ Human	⊔ Murine ⊔ Bact	erial L	I Viral ⊔ O	ther			
Risk Assessment Dis	scussion:			*	es, and	Sa	fety Practices
⊠ Yes □ No			Reviewe				
DI/C · TE ·	•		⊠ Yes	□ No			
PI/Supervisor Train	ing:			Training:			
⊠ Yes □ No			⊠ Yes	□ No			

Discussion/Required Modifications:

- Recommendation from IBC: Spray gloves with alternative disinfectant instead of 70% ethanol to disinfect. 70% can degrade gloves making more prone to break when handling items
- Recommendation from IBC: Follow waste disposal SOP unless there is a reason to deviate.
- If deviating from waste disposal SOP, please indicate/update sections highlighted in application
- Please update wording to reflect Bunsen burners are not being used within BSCs.
- Administrative edits and updates

Motion Approval:	For:	Against:	Abstain:	Recuse:	Not Present:
Approved w/ Administrative Revisions	9	0	0	0	1

e. Amendments:

Basic Research	Protocol ID:	PI:	Biosafety	NIH Cat.:
Amendment #1	IBC2222	Stacy	Level:	III-D-1-a, III-D-
			BSL2, ABSL2	4-b
Project Titles:				
Oral microbiota-host	interactions in per	riodontitis		
Associated Grant No	umbers:			
Non-NIH Funding				
Summary of Approv	ed Items:			
Generation and cultur	•			-
human and rodent-de	rived material; ad	ministration <i>in viv</i>	o; Human-derived	material.
Requested Additions	s/Changes:			
 Non-recombine 	nant <i>Pseudomonas</i>	s and <i>Enterococcu</i>	s spp.	
 Recombinant 	<i>Neisseria</i> and <i>Fus</i>	obacterium spp.		
 Human tissue 	culture cells			
 Updated to present 	ocedures for cultu	ring and co-cultur	ring wild type and i	recombinant
	ue culture cells.			
Function/Nature of R	ecombinant Gene	s to be Expressed:	-	
□ N/A □ Oncogene	☐ Tumor Suppres	ssor Gene 🛮 Struc	etural Signaling	☐ Antimicrobial
☐ Immunomodulatory	□ Toxin □ Ant	ibiotic Resistance	□ Reporters ⊠ C	Cell Metabolism
⊠ Other				
Species of Recombination	ant Genes to be E	xpressed:		
\square N/A \square Human \square	☐ Murine ⊠ Bacte	erial 🗆 Viral 🗆 0	Other	
Risk Assessment Dis	cussion:			d Safety Practices
⊠ Yes □ No		Review	ed:	
		⊠ Yes	□ No	

PI/Supervisor Training:	Handler Training:
⊠ Yes □ No	⊠ Yes □ No

Discussion/Required Modifications:

- An import permit is not necessary for these items, please update accordingly
- Include a brief description of changes to *in vivo* experiments
- Indicate which approved rooms are being used for co-culturing experiments in room table.
- Add a statement to the "Special Hazards" section that healthcare personnel will be informed in case of accidental exposure.
- Reference SOPs for ABSL2 areas in PPE section
- Use the following language for disposal of agar plates: Plates will be sealed to ensure the lids stay closed and dispose of into a red biohazard bag. At end of experiment, they will be tied shut, externally disinfected, and placed in nearby biohazard step-can.
- Remove statement about human samples no longer being considered hazardous after filtration. Certain microorganisms may not be captured by the filter.
- Indicate minimum contact time for fixation.
- Please indicate the use of a tray for co-culturing experiments using a syringe pump in case of spillage.

Motion Approval: Approved w/ Administrative	For:	Against:	Abstain:	Recuse:	Not Present:
Revisions	7	0	0	1	2

Basic Research	Protocol ID:	PI:	Biosafety	NIH Cat.:
Amendment #2	IBC 2023	Jung	Level:	III-D-1-a, III-D-
		_	BSL2, ABSL2	2-a, III-D-3-a, III-
				D-4-b, III-E

Project Titles:

Identifying viral determinants involve in viral-host interactions using infectious clones

Associated Grant Numbers:

R01 AI140705, R01 AI52190, R01AI151013

Summary of Approved Items:

Propagation of non-recombinant Murine Coronavirus, Human Coronavirus, La Crosse Virus, Utinga Virus, Simbu Virus, Manzanilla Virus, Buttonwillow Virus, Ingwavuma Virus, rodent herpesvirus Peru E and L virus, Oropouche Virus and Uukuniemi Virus. Propagation of recombinant Zika virus, Kaposi's Sarcoma associated herpesvirus, Murine Gammaherpesvirus 68 (MuHV-68), Measles virus, Mumps virus, Oropouche Virus (OROV), and Herpesvirus; Generation of replication competent Retroviral particles; Handling of Measles, Mumps, HRTV, SFTSV Viral Vector vaccines; Generation of mRNA vaccines; Administration of all agents *in vivo*. Acquisition and processing of Epstein – Barr virus positive samples, Non K-12 E. coli; Human-derived material

Requested Addition						
_	~	51 11				
	modified Rhesus		iovirus			
 Mammalian t 	issue culture cells	S				
 Updates to present the presen	ocedures					
Function/Nature of R	ecombinant Gene	es to be	Expressed:			
□ N/A □ Oncogene	☐ Tumor Suppre	essor Ge	ne 🛮 Struc	ctural 🗆 Sig	gnaling	☐ Antimicrobial
☐ Immunomodulatory					_	
☐ Other				1		
Species of Recombin	ant Genes to be F	Expresse	ed:			
\square N/A \square Human \square		-)ther		
		Criai E	viiai 🗀 C	otile!		
Risk Assessment Dis	scussion:		Facilitie	s. Procedur	es. and	d Safety Practices
✓ Yes □ No	, cussion.		Reviewe		c 5, u 11	a salety 1 factices
			⊠ Yes	□ No		
PI/Supervisor Train	ing			Training:		
	mg.					
	1 N # 1'C' 4'		⊠ Yes	□ No		
Discussion/Required				. 1	. ,	
• Confirm state	ment regarding c	hanges	to infectivit	y in recomb	ınant v	iruses.
3.6 4° A	_	Б	A • 4	1 4 7 4 *	Ъ	NI (D)
Motion Approval:		For:	Against:	Abstain:	Recu	_
Approved		7	0	0	1	2
11-1010.00						
11001010						
	Protocol ID:		pI.	Riosafe	tv	NIH Cat ·
Basic Research	Protocol ID:		PI:	Biosafe Level	•	NIH Cat.:
	Protocol ID: IBC 2026		PI: Jung	Level	:	III-D-1-a, III-D-
Basic Research					:	III-D-1-a, III-D- 2-a, III-D-3-a, III-
Basic Research Amendment #3				Level	:	III-D-1-a, III-D-
Basic Research Amendment #3	IBC 2026		Jung	Level BSL2, AB	:	III-D-1-a, III-D- 2-a, III-D-3-a, III-
Basic Research Amendment #3 Project Titles: Identifying host deter	IBC 2026		Jung	Level BSL2, AB	:	III-D-1-a, III-D- 2-a, III-D-3-a, III-
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N	IBC 2026 minants involved	l in imn	Jung	Level BSL2, AB	:	III-D-1-a, III-D- 2-a, III-D-3-a, III-
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A	IBC 2026 rminants involved umbers: I152190, R01AI	l in imn	Jung	Level BSL2, AB	:	III-D-1-a, III-D- 2-a, III-D-3-a, III-
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approx	IBC 2026 minants involved umbers: I152190, R01AI ved Items:	l in imn 171201	Jung	Level BSL2, AB	SSL2	III-D-1-a, III-D- 2-a, III-D-3-a, III- D-4-b, III-E
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approv Generation of replica	rminants involved umbers: I152190, R01AI ved Items: tion defective add	1 in imn 171201 eno-asso	Jung nunoregulat	Level BSL2, AB	SL2	III-D-1-a, III-D- 2-a, III-D-3-a, III- D-4-b, III-E
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approv Generation of replica culture cells, and adn	rminants involved umbers: I152190, R01AI ved Items: tion defective addinistration in viv	1 in imn 171201 eno-asse o. Gene	Jung nunoregulat ociated vira	Level BSL2, AB ion l particles, to plication decorate.	ransductective	III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-E ction of tissue lentiviral particles
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approv Generation of replica culture cells, and adn and transduction of ti	rminants involved umbers: I152190, R01AI ved Items: tion defective administration in vivissue culture cells	1 in imn 171201 eno-asso o. Gene	nunoregulate ociated viral eration of resistion of SA	Level BSL2, AB ion l particles, to plication des	ransdu fective strains,	III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-E ction of tissue lentiviral particles, generation of
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approv Generation of replica culture cells, and adn and transduction of ti recombinant Hepatiti	rminants involved umbers: 1152190, R01AI ved Items: tion defective addinistration in viv ssue culture cells s B Virus, human	d in imm 171201 eno-asso o. Gene a. Acqui	nunoregulated viral eration of SA atory Syncy	Level BSL2, AB ion l particles, to plication decade ARS-CoV-2 services (Figure 1981)	ransdur fective strains,	III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-E ction of tissue lentiviral particles, generation of SARS-CoV-2
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approv Generation of replica culture cells, and adn and transduction of ti recombinant Hepatiti strains and Mumps V	rminants involved umbers: I152190, R01AI ved Items: tion defective add ninistration in viv ssue culture cells s B Virus, human irus; administrati	d in imn 171201 eno-assa o. Gene s. Acqui n Respir on of H	nunoregulate ociated viral oration of resition of SA atory Syncy epatitis B V	Level BSL2, AB ion l particles, to plication de ARS-CoV-2 serial Virus (February SARS-CoV-2) ion (February SARS-CoV-2)	ransdurfective strains, RSV), 9	ction of tissue lentiviral particles, generation of SARS-CoV-2 in vivo.
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approv Generation of replica culture cells, and adn and transduction of ti recombinant Hepatiti strains and Mumps V Acquisition of Parain	rminants involved umbers: I152190, R01AI ved Items: tion defective administration in viving saue culture cells is B Virus, human irus; administrati fluenza Type III (d in imn 171201 eno-asso o. Gene o. Acqui n Respir on of H (PIV3),	nunoregulate ociated viral eration of resistion of SA atory Syncy epatitis B V Human Me	Level BSL2, AB ion I particles, to plication decades. CoV-2 setial Virus (Firus, SARS) etapneumonic	ransductive strains, RSV), S-CoV-2a (hMI)	ction of tissue lentiviral particles, generation of SARS-CoV-2 in vivo.
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approx Generation of replica culture cells, and adn and transduction of ti recombinant Hepatiti strains and Mumps V Acquisition of Parain Administration of pla	rminants involved umbers: I152190, R01AI ved Items: tion defective addinistration in viving saue culture cells is B Virus, human irus; administrati fluenza Type III elementa infected cells infected cel	eno-asso o. Gene a. Acqui a Respir on of H (PIV3), lls expre	nunoregulate ociated viral eration of SA atory Syncy epatitis B V Human Meessing HBV	l particles, to plication de ARS-CoV-2 strial Virus (Firus, SARS etapneumonit in vivo. Ge	ransductestrains, RSV), S-CoV-2 a (hM) neratio	III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-E ction of tissue lentiviral particles, generation of SARS-CoV-2 in vivo. PV) virus.
Basic Research Amendment #3 Project Titles: Identifying host deter Associated Grant N R01AI140705, R01A Summary of Approv Generation of replica culture cells, and adn and transduction of ti recombinant Hepatiti strains and Mumps V Acquisition of Parain	rminants involved umbers: I152190, R01AI ved Items: tion defective administration in viv ssue culture cells is B Virus, human firus; administrati fluenza Type III esmid infected cells NA vaccine in vi	eno-asso o. Gene a. Acqui a Respir on of H (PIV3), lls expro	nunoregulateration of seatory Syncy Epatitis B V Human Meessing HBV eration of p	l particles, to plication de ARS-CoV-2 strial Virus (Firus, SARS etapneumonit in vivo. Ge	ransductestrains, RSV), S-CoV-2 a (hM) neratio	III-D-1-a, III-D-2-a, III-D-3-a, III-D-4-b, III-E ction of tissue lentiviral particles, generation of SARS-CoV-2 in vivo. PV) virus.

Requested Additions	s/Changes:						
 Leishmania ta 	rentolae protein	express	ion system	and associat	ed pro	tocol	ls
 Mammalian e 	xpression plasmi	ds	-				
 Gene targets 							
8							
Function/Nature of R	ecombinant Gene	es to be	Expressed:				
□ N/A ⊠ Oncogene	☐ Tumor Suppre	essor Ge	ne 🛮 🗵 Struc	ctural 🗆 Si	gnaling		Antimicrobial
	□ Toxin ⊠ Aı	ntibiotic	Resistance	⊠ Reporter	s \square	Cell	Metabolism
⊠ Other				1			
Species of Recombin	ant Genes to be I	Expresse	ed:				
\square N/A \boxtimes Human \square	⊠ Murine □ Bac	terial 2	⊠ Viral ⊠ (Other			
Risk Assessment Dis	cussion:		Facilitie	s, Procedur	es, and	d Sa	fety Practices
⊠ Yes □ No			Reviewe	ed:			
			⊠ Yes	□ No			
PI/Supervisor Train	ing:		Handler	Training:			
⊠ Yes □ No	_		⊠ Yes	□ No			
Discussion/Required	Modifications:						
 Update statem 	ent regarding ha	zards as	ssociated wi	th expressed	d protei	ins	
• In special haz	ards section, indi	cate Lei	ishmania ta	rentolae is a	gecko	patl	nogen, and that
-	dling the organis				_	-	_
1				1			
Motion Approval:		Eam	A	Abstains	Dagu	~ ~ •	Not Duogonte
Approved w/ Admin	istrative	For:	Against:	Abstain:	Recu	se:	Not Present:
Revisions		8	0	0	0		2
Basic Research	Protocol ID:		PI:	Biosafe	•		NIH Cat.:
Amendment #4	IBC 2113		Jung	Level		Ш	-D-1-a, III-D-
				BSL2			3-a

Basic Research	Protocol ID:	PI:	Biosafety	NIH Cat.:
Amendment #4	IBC 2113	Jung	Level: BSL2	III-D-1-a, III-D- 3-a
	I.	I .	l .	

Project Titles:

Modeling liver diseases using a human pluripotent stem cell derived-multicellular platform

Associated Grant Numbers:

Non-NIH Funding

Summary of Approved Items:

Generation of replication defective lentivirus viral particles and transduction of tissue culture cells; propagation of recombinant hepatitis B virus, herpes simplex virus – 1 and acquisition of recombinant Kaposi Sarcoma Associated Herpesvirus (KSHV) and infection of tissue culture cells; Human-derived materials

robial
ism
actices
resent:

Basic Research	Protocol ID:	PI:	Biosafety	NIH Cat.:
Amendment #5	IBC 2210	Melenhorst	Level:	III-D-1-a, III-D-
			BSL2, ABSL2	3-a, III-D-4-b
D ' 4 T'41	•			

Project Titles:

In vitro testing of gene-modified T cells against solid tumors and hematological malignancies

Associated Grant Numbers:

R01CA241762

Summary of Approved Items:

Generation and validation of CAR-T cells targeting specific tumor markers. Generation of lentiviral particles and transduction of tissue culture cells, administration *in vivo*, electroporation using a CRISPR/Cas9 system into tissue culture cells; processing of potentially infectious or known infectious human material; Human-derived samples

Requested Addition	s/Changes•							
_	Requested Additions/Changes:							
Replication deficient lentiviral particlesGene targets								
	l racambinant ma	mmolio	n tiggue gult	ura gall line	NG.			
• who type and	l recombinant ma	IIIIIIaiia	in ussue cun	lure cen inic	58			
Function/Nature of R	acombinant Gan	es to be	Evpressed:					
□ N/A ⊠ Oncogene			_	turol 🖂 Ci.	malina [☐ Antimionahial		
	* *				•			
7	☐ Immunomodulatory ☐ Toxin ☐ Antibiotic Resistance ☐ Reporters ☐ Cell Metabolism							
☐ Other								
Species of Recombin	ant Genes to be I	Z vnr ecce	ad.					
\square N/A \boxtimes Human		-		other				
LIVA LIUIII		iciiai L	J VII al 🗆 O	THE				
Risk Assessment Dis	scussion:		Facilitie	s. Procedur	es. and S	afety Practices		
	, cussion.		Reviewe	*	cs, and s	arety ratetices		
			⊠ Yes	□ No				
PI/Supervisor Train	ing:			Training:				
⊠ Yes □ No			⊠ Yes					
Discussion/Required	l Modifications:							
• N/A								
Motion Approval:		Б		41 4 .	D	N D.		
Approved		For:	Against:	Abstain:	Recuse:	_		
11		8	0	0	0	2		
Basic Research	Protocol ID:		PI:	Diagafa	4	NIH Cat.:		
Amendment #6	IBC 2037		Keri	•				
Amenument #0	IBC 2037		Kell	BSL2, ABSL2		II-D-1-a, III-D- 4-b		
Project Titles:				DSLZ, AD	SL2	4-0		
Transcriptional representation	ssion of aggressiv	za brans	t concer nhe	notynec				
Associated Grant N		e oreas	t cancer pile	hotypes				
R01CA257502, R210								
Summary of Approv								
Acquisition of replica		ntivimis	narticles tr	aneduction i	of tissue o	nulture cells, and		
			-					
administration of transduced cells <i>in vivo</i> . Acquisition of replication defective adenovirus particles, transduction of tissue culture cells, administration of adenovirus <i>in vivo</i> ,								
administration of adenovirus transduced cells <i>in vivo</i> ; Plasmid transfection in tissue culture								
and administration of plasmid transfected cells <i>in vivo</i> ; Human-derived materials.								
Requested Addition			5 111 7170, 11		<i>y</i>	*15.		
_	eficient lentiviral	particle	es					
• Gene targets	errerent rentr virus	particit						
	culture cell line							
- Human ussuc	cantare cell lille							
Function/Nature of R	Evention (Notions of Bosombinout Course to be Events and							
Function/Nature of Recombinant Genes to be Expressed:								

□ N/A □ Oncogene □ Immunomodulatory □ Other	☐ Tumor Suppre ☐ Toxin ☐ Ar					Antimicrobial Metabolism		
Species of Recombin □ N/A ⊠ Human □		_		other				
Risk Assessment Discussion: □ Yes □ No No Reviewed: □ Yes □ No No No No No No No No								
⊠ Yes □ No	PI/Supervisor Training: □ Yes □ No □ No □ No							
Discussion/Required N/A	l Modifications:							
Motion Approval: Approved		For:	Against:	Abstain:	Recuse:	Not Present:		
Basic Research Amendment #7								
	Project Titles: Microbes in the gut and control of Inflammatory Bowel Disease Associated Grant Numbers:							
Summary of Approv Isolation and growth cells; administration of Acquisition of choler vivo; Human-derived	of wt and recomb of bacteria <i>in vivo</i> a, diphtheria and	, treatn	nent of tissu	e culture ce	lls with ba	cterial isolate;		
• New source of	s/Changes: of stool samples							
Function/Nature of Recombinant Genes to be Expressed: ⊠ N/A □ Oncogene □ Tumor Suppressor Gene □ Structural □ Signaling □ Antimicrobial □ Immunomodulatory □ Toxin □ Antibiotic Resistance □ Reporters □ Cell Metabolism □ Other								
Species of Recombin ⊠ N/A □ Human □		-		Other				
Risk Assessment Dis	Risk Assessment Discussion: □ Yes □ No No Reviewed:							

			⊠ Yes	□ No				
PI/Supervisor Train	ing.			Training:				
Yes □ No	1							
Discussion/Required	d Modifications:		⊠ Yes	□ No				
Please reach out to EHS regarding whether an import permit is needed.								
Motion Approval:		For:	Against:	Abstain:	Recuse	Not Present:		
Approved	Approved			0	1	2		
Basic Research	Protocol ID:		PI:	Biosafe	ty	NIH Cat.:		
Amendment #8	IBC 2409		Chen	Level	-	II-D-1-a, III-D-		
				BSL2, AB	SL2 3	a, III-D-4-b, III-		
						E		
Project Titles:								
Mechanism and thera		of micro	oglia regulat	ion in gliob	lastoma			
Associated Grant N			1.					
R01 NS127824, R01		-NIH Fu	ınding					
Summary of Approx		,· ·	1	1	C.:	1, 11 1		
Generation of replica					of tissue c	ulture cells, and		
administration of tran		1uman-	derived mat	eriais.				
Requested AdditionsRoom additions	_							
• Opdate to disi	infectants used							
Function/Nature of R	ecombinant Gene	es to he	Evnressed:					
\boxtimes N/A \square Oncogene				otural □ Sid	malino [7 Antimicrobial		
☐ Immunomodulatory				-	_			
☐ Other		indione	Resistance	□ Keporters		Metabolishi		
- Other								
Species of Recombin	ant Genes to be F	Express	ed:					
\boxtimes N/A \square Human [-		Other				
Risk Assessment Dis	scussion:		Facilitie	s, Procedur	es, and S	afety Practices		
⊠ Yes □ No			Reviewe	Reviewed:				
			⊠ Yes	□ No				
PI/Supervisor Training: Handler Training:								
Discussion/Required	d Modifications:							
Confirm rooms listed in table and stepwise are accurate								
 Update boxes indicating if rooms are in open spaces. 								
Motion Approval:								
Approved w/ Admin	nistrative	For:	Against:	Abstain:	Recuse			
Revisions		8	0	0	0	2		

Basic Research	Protocol ID:		PI:	Biosafe	ty	NIH Cat.:	
Amendment #9	IBC 2226	Pop	olawski	Level:	-	I-D-1-a, III-D-	
				BSL2, AB	SL2 2-a	ı, III-D-3-a, III-	
					D-	-4-a, III-D-4-b,	
						III-E-1	
Project Titles:					. ,		
Investigation of mole		mecha	nisms of ne	urodegenera	ition/regen	eration	
Associated Grant Non-NIH Funding	umbers:						
Summary of Approv	ved Items:						
Generation and acqui			-			-	
propagation of replica					f tissue cu	lture cells, and	
administration of tran		vo. Hui	nan-derived	i materiai.			
Requested AdditionsUpdates to pro	_						
Room additio							
• Room addition	11						
Function/Nature of R	ecombinant Gene	s to be	Expressed:				
\boxtimes N/A \square Oncogene	☐ Tumor Suppre		-	tural □ Sic	malino 🗆	Antimicrobial	
☐ Immunomodulatory				-	_		
☐ Other		noione i	Constance	□ reporters		Victoonsiii	
Species of Recombin	ant Genes to be E	xpresse	<u>ed:</u>				
⊠ N/A □ Human [☐ Murine ☐ Bact	erial 🗆	l Viral 🗆 C	ther			
Risk Assessment Dis	scussion:			*	es, and Sa	fety Practices	
⊠ Yes □ No			Reviewe				
WY (C			⊠ Yes	□ No			
PI/Supervisor Train	ing:			Training:			
⊠ Yes □ No			⊠ Yes	□ No			
Discussion/Required				1 0			
	ectant for BSC, bl			he surtace.			
•	ng of "labeled liq						
Include statement that cuvettes will be disinfected prior to removing from BSC.							
Motion Approval:		For:	Against:	Abstain:	Recuse:	Not Present:	
Approved w/ Admin	istrative	7	()	0	1	2	
Revisions		,		Ĭ	*		
V. Revised SO	OPs:						
SOP a: Riological W	aste Disnosal	Comm	ents•				
SOP a: Biological Waste Disposal Comments:							

Update Title

	•	work session 8.5.1.4: Incommercial certified for	arify if meandate to the solution and the disponied applicate applicate solid/infections.	ning full piges following: posed of at cable autocletious waste	pettes or "temporary the end of a laves are not e sterilization.	
Motion Approval:	For:	Against:	Abstain:	Recuse:	Not Present:	
Approved w/ Administrative	8 0 0 2					
Revisions						

SOP b: ABSL2 Operations	Comments: N/A				
Motion Approval:	For:	Against:	Abstain:	Recuse:	Not Present:
Approved	7	0	0	1	2

VI. Other Business

None